6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Antiproliferative and palliative activity of flavonoids in colorectal cancer.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Flavonoids are plant bioactive compounds of great interest in nutrition and pharmacology, due to their remarkable properties as antioxidant, anti-inflammatory, antibacterial, antifungal and antitumor drugs. More than 5000 different flavonoids exist in nature, with a huge structural diversity and a plethora of interesting pharmacological properties. In this work, five flavonoids were tested for their potential use as antitumor drugs against three CRC cell lines (HCT116, HT-29 and T84). These cell lines represent three different stages of this tumor, one of which is metastatic. Xanthohumol showed the best antitumor activity on the three cancer cell lines, even better than that of the clinical drug 5-fluorouracil (5-FU), although no synergistic effect was observed in the combination therapy with this drug. On the other hand, apigenin and luteolin displayed slightly lower antitumor activities on these cancer cell lines but showed a synergistic effect in combination with 5-FU in the case of HTC116, which is of potential clinical interest. Furthermore, a literature review highlighted that these flavonoids show very interesting palliative effects on clinical symptoms such as diarrhea, mucositis, neuropathic pain and others often associated with the chemotherapy treatment of CRC. Flavonoids could provide a double effect for the combination treatment, potentiating the antitumor effect of 5-FU, and simultaneously, preventing important side effects of 5-FU chemotherapy.

          Related collections

          Author and article information

          Journal
          Biomed Pharmacother
          Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
          Elsevier BV
          1950-6007
          0753-3322
          Nov 2021
          : 143
          Affiliations
          [1 ] Research Unit "Biotechnology in Nutraceuticals and Bioactive Compounds-BIONUC", Departamento de Biología Funcional, Área de Microbiología, Universidad de Oviedo, Oviedo, Spain; Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Oviedo, Spain; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain. Electronic address: UO186966@uniovi.es.
          [2 ] Department of Basic Health Sciences, Faculty of Health Sciences, University Rey Juan Carlos (URJC), Alcorcón, Spain. Electronic address: blanca_almorojana@hotmail.com.
          [3 ] Research Unit "Biotechnology in Nutraceuticals and Bioactive Compounds-BIONUC", Departamento de Biología Funcional, Área de Microbiología, Universidad de Oviedo, Oviedo, Spain; Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Oviedo, Spain; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain. Electronic address: rodrigo.entrialgo@gmail.com.
          [4 ] Research Unit "Biotechnology in Nutraceuticals and Bioactive Compounds-BIONUC", Departamento de Biología Funcional, Área de Microbiología, Universidad de Oviedo, Oviedo, Spain; Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Oviedo, Spain; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain. Electronic address: cjvg@uniovi.es.
          [5 ] Department of Agricultural Sciences, University of Naples Federico II, 80055 Portici, Italy. Electronic address: rafcapas@unina.it.
          [6 ] Department of Basic Health Sciences, Faculty of Health Sciences, University Rey Juan Carlos (URJC), Alcorcón, Spain; High Performance Research Group in Physiopathology and Pharmacology of the Digestive System (NeuGut-URJC), URJC, Alcorcón, Spain. Electronic address: jose.uranga@urjc.es.
          [7 ] Research Unit "Biotechnology in Nutraceuticals and Bioactive Compounds-BIONUC", Departamento de Biología Funcional, Área de Microbiología, Universidad de Oviedo, Oviedo, Spain; Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Oviedo, Spain; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain. Electronic address: lombofelipe@uniovi.es.
          [8 ] Department of Basic Health Sciences, Faculty of Health Sciences, University Rey Juan Carlos (URJC), Alcorcón, Spain; High Performance Research Group in Physiopathology and Pharmacology of the Digestive System (NeuGut-URJC), URJC, Alcorcón, Spain; Associated I+D+i Unit to the Institute of Medicinal Chemistry (IQM), Scientific Research Superior Council (CSIC), Madrid, Spain; Working Group of Basic Sciences in Pain and Analgesia of the Spanish Pain Society (Grupo de Trabajo de Ciencias Básicas en Dolor y Analgesia de la Sociedad Española del Dolor), Madrid, Spain. Electronic address: raquel.abalo@urjc.es.
          Article
          S0753-3322(21)01025-8
          10.1016/j.biopha.2021.112241
          34649363
          1ec3468e-2db3-4479-bc74-70467fa18968
          Copyright © 2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved.
          History

          Luteolin,Mucositis,Naringenin,Neuropathic pain,Xanthohumol,Antitumor,Apigenin,Colorectal cancer,Eriodictyol,Flavonoids

          Comments

          Comment on this article